The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
HER-2 in high risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
Francesco Sclafani
No relevant relationships to disclose
Amitesh Chandra Roy
No relevant relationships to disclose
Ian Chau
Consultant or Advisory Role - Merck Serono (U); Roche
Honoraria - Roche; Sanofi
Research Funding - Merck; Roche
Andrew Wotherspoon
No relevant relationships to disclose
Clare Peckitt
No relevant relationships to disclose
Alice Dewdney
No relevant relationships to disclose
Jacqueline Rose Oates
No relevant relationships to disclose
David Cunningham
Consultant or Advisory Role - Merck; Roche; Roche (U); Sanofi
Honoraria - Merck; Roche; Sanofi
Research Funding - Merck KGaA; Roche